Detalhe da pesquisa
1.
Efficacy and safety of azacitidine in pediatric patients with newly diagnosed advanced myelodysplastic syndromes before hematopoietic stem cell transplantation in the AZA-JMML-001 trial.
Pediatr Blood Cancer
; 71(5): e30931, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38433307
2.
Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia.
Pediatr Blood Cancer
; 68(7): e28946, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33694257
3.
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
Br J Haematol
; 180(2): 224-235, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29193019
4.
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Lancet Oncol
; 17(3): 319-331, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26899778
5.
DeltaNp63 induces beta-catenin nuclear accumulation and signaling.
Cancer Cell
; 1(4): 369-79, 2002 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12086851
6.
Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.
Blood Adv
; 5(14): 2901-2908, 2021 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34297046
7.
Interaction and colocalization of PGP9.5 with JAB1 and p27(Kip1).
Oncogene
; 21(19): 3003-10, 2002 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-12082530